JP7263313B2 - 併用される抗真菌剤 - Google Patents

併用される抗真菌剤 Download PDF

Info

Publication number
JP7263313B2
JP7263313B2 JP2020504267A JP2020504267A JP7263313B2 JP 7263313 B2 JP7263313 B2 JP 7263313B2 JP 2020504267 A JP2020504267 A JP 2020504267A JP 2020504267 A JP2020504267 A JP 2020504267A JP 7263313 B2 JP7263313 B2 JP 7263313B2
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
pharmaceutical combination
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020504267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513037A5 (https=
JP2020513037A (ja
Inventor
アングロ・ゴンザレス，デイビット・エー
Original Assignee
サイネクシス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイネクシス，インコーポレーテッド filed Critical サイネクシス，インコーポレーテッド
Publication of JP2020513037A publication Critical patent/JP2020513037A/ja
Publication of JP2020513037A5 publication Critical patent/JP2020513037A5/ja
Priority to JP2022205904A priority Critical patent/JP7574268B2/ja
Application granted granted Critical
Publication of JP7263313B2 publication Critical patent/JP7263313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2020504267A 2017-04-10 2018-04-04 併用される抗真菌剤 Active JP7263313B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022205904A JP7574268B2 (ja) 2017-04-10 2022-12-22 併用される抗真菌剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10
US62/483,647 2017-04-10
PCT/US2018/026088 WO2018191077A1 (en) 2017-04-10 2018-04-04 Antifungal agents used in combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022205904A Division JP7574268B2 (ja) 2017-04-10 2022-12-22 併用される抗真菌剤

Publications (3)

Publication Number Publication Date
JP2020513037A JP2020513037A (ja) 2020-04-30
JP2020513037A5 JP2020513037A5 (https=) 2021-05-13
JP7263313B2 true JP7263313B2 (ja) 2023-04-24

Family

ID=62063223

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020504267A Active JP7263313B2 (ja) 2017-04-10 2018-04-04 併用される抗真菌剤
JP2022205904A Active JP7574268B2 (ja) 2017-04-10 2022-12-22 併用される抗真菌剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022205904A Active JP7574268B2 (ja) 2017-04-10 2022-12-22 併用される抗真菌剤

Country Status (13)

Country Link
US (2) US11110102B2 (https=)
EP (1) EP3609539A1 (https=)
JP (2) JP7263313B2 (https=)
KR (2) KR20240110109A (https=)
CN (1) CN110769854B (https=)
AR (1) AR113221A1 (https=)
AU (1) AU2018253031B2 (https=)
CA (1) CA3059225A1 (https=)
EA (1) EA201992413A1 (https=)
MA (1) MA49889A (https=)
MX (1) MX2019012116A (https=)
TW (1) TWI806861B (https=)
WO (1) WO2018191077A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제
BR112021016876A2 (pt) * 2019-02-27 2021-11-03 Scynexis Inc Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530593A (ja) 2008-08-12 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 抗真菌剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
CA2982660C (en) * 2014-11-21 2023-01-24 F2G Limited 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents
HRP20220544T1 (hr) 2015-01-19 2022-08-05 Scynexis, Inc. Nove soli i polimorfi scy-078

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530593A (ja) 2008-08-12 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 抗真菌剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy，2013年，57，1065-1068
Antimicrobial Agents and Chemotherapy，2013年，57，4656-4663
Antimicrobial Agents and Chemotherapy，2013年，57，5778-5780
Journal of Antimicrobuial Chemotherapy，2016年，71，3135-3147
Journal of Infectious Diseases，2003年，187，1834-1843

Also Published As

Publication number Publication date
TWI806861B (zh) 2023-07-01
TW201842915A (zh) 2018-12-16
US20220202833A1 (en) 2022-06-30
KR20240110109A (ko) 2024-07-12
EA201992413A1 (ru) 2020-03-16
AU2018253031A1 (en) 2019-10-31
AR113221A1 (es) 2020-02-19
CA3059225A1 (en) 2018-10-18
KR102683355B1 (ko) 2024-07-10
JP2020513037A (ja) 2020-04-30
AU2018253031B2 (en) 2024-04-11
US11110102B2 (en) 2021-09-07
CN110769854B (zh) 2023-01-13
MX2019012116A (es) 2019-11-21
JP2023030113A (ja) 2023-03-07
KR20190133251A (ko) 2019-12-02
JP7574268B2 (ja) 2024-10-28
EP3609539A1 (en) 2020-02-19
CN110769854A (zh) 2020-02-07
US20180325919A1 (en) 2018-11-15
BR112019021138A2 (pt) 2020-05-12
MA49889A (fr) 2020-06-24
WO2018191077A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP7574268B2 (ja) 併用される抗真菌剤
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
HK40022879B (en) Antifungal agents used in combination
BR112019021138B1 (pt) Combinação farmacêutica, e, uso de uma combinação farmacêutica
HK40022879A (en) Antifungal agents used in combination
EA047299B1 (ru) Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
WO2025120231A1 (en) Antifungal compounds
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221222

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230221

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230412

R150 Certificate of patent or registration of utility model

Ref document number: 7263313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250